Waldenstrom Macroglobulinemia: Tailoring Therapy for the Individual
Menée à partir d'une revue des essais cliniques de phase II ou de phase III ayant évalué au cours des 20 dernières années des traitements pour la macroglobulinémie de Waldenström, cette étude présente diverses options thérapeutiques et suggère, en l'absence de recommandations généralisables, d'individualiser les traitements en fonction des préférences des patients, des comorbidités et du degré de toxicité des médicaments
With the introduction of multiple new effective therapeutic options for the treatment of macroglobulinemia, a structured approach to management of this rare lymphoma is currently needed. A review of phase II and III treatment trials over the past 20 years was performed, and high-quality trials are summarized in this manuscript. Because of the lack of large prospective trials comparing different classes of therapy, a uniform recommendation applicable to all patients cannot be made, and the approach must be individualized incorporating patient preferences, comorbidities, and the range of therapeutic toxicities. Therapeutic options for patients with newly diagnosed and previously treated macroglobulinemia are presented on the basis of the best available evidence in the literature.
Journal of Clinical Oncology , résumé, 2021